JP6109175B2 - 酸化リン脂質の製剤および剤形 - Google Patents

酸化リン脂質の製剤および剤形 Download PDF

Info

Publication number
JP6109175B2
JP6109175B2 JP2014528672A JP2014528672A JP6109175B2 JP 6109175 B2 JP6109175 B2 JP 6109175B2 JP 2014528672 A JP2014528672 A JP 2014528672A JP 2014528672 A JP2014528672 A JP 2014528672A JP 6109175 B2 JP6109175 B2 JP 6109175B2
Authority
JP
Japan
Prior art keywords
inflammatory
disease
liquid
capsule
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014528672A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014525463A5 (cg-RX-API-DMAC7.html
JP2014525463A (ja
Inventor
ナーミット シェール
ナーミット シェール
ビクター エム. ヤング
ビクター エム. ヤング
アリン マクノートン
アリン マクノートン
マスード バフシャイ
マスード バフシャイ
イアン ロバート ワイルディング
イアン ロバート ワイルディング
Original Assignee
バスキュラー バイオジェニックス リミテッド
バスキュラー バイオジェニックス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バスキュラー バイオジェニックス リミテッド, バスキュラー バイオジェニックス リミテッド filed Critical バスキュラー バイオジェニックス リミテッド
Publication of JP2014525463A publication Critical patent/JP2014525463A/ja
Publication of JP2014525463A5 publication Critical patent/JP2014525463A5/ja
Application granted granted Critical
Publication of JP6109175B2 publication Critical patent/JP6109175B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
JP2014528672A 2011-09-01 2012-08-31 酸化リン脂質の製剤および剤形 Expired - Fee Related JP6109175B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161529989P 2011-09-01 2011-09-01
US61/529,989 2011-09-01
PCT/US2012/053533 WO2013033642A1 (en) 2011-09-01 2012-08-31 Formulations and dosage forms of oxidized phospholipids

Publications (3)

Publication Number Publication Date
JP2014525463A JP2014525463A (ja) 2014-09-29
JP2014525463A5 JP2014525463A5 (cg-RX-API-DMAC7.html) 2015-10-01
JP6109175B2 true JP6109175B2 (ja) 2017-04-05

Family

ID=46964020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014528672A Expired - Fee Related JP6109175B2 (ja) 2011-09-01 2012-08-31 酸化リン脂質の製剤および剤形

Country Status (15)

Country Link
US (3) US9254297B2 (cg-RX-API-DMAC7.html)
EP (1) EP2750668B1 (cg-RX-API-DMAC7.html)
JP (1) JP6109175B2 (cg-RX-API-DMAC7.html)
KR (1) KR101939430B1 (cg-RX-API-DMAC7.html)
CN (1) CN103874485B (cg-RX-API-DMAC7.html)
AU (1) AU2012301602B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014004916B1 (cg-RX-API-DMAC7.html)
CA (1) CA2847218C (cg-RX-API-DMAC7.html)
EA (1) EA029274B1 (cg-RX-API-DMAC7.html)
ES (1) ES2768266T3 (cg-RX-API-DMAC7.html)
IL (1) IL231222B (cg-RX-API-DMAC7.html)
MX (1) MX357759B (cg-RX-API-DMAC7.html)
SG (1) SG11201400208PA (cg-RX-API-DMAC7.html)
WO (1) WO2013033642A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201401478B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US7807847B2 (en) 2004-07-09 2010-10-05 Vascular Biogenics Ltd. Process for the preparation of oxidized phospholipids
US9006217B2 (en) 2007-01-09 2015-04-14 Vascular Biogenics Ltd. High-purity phospholipids
US8569529B2 (en) 2007-01-09 2013-10-29 Vascular Biogenics Ltd. High-purity phospholipids
US8999960B2 (en) 2008-10-08 2015-04-07 Vascular Biogenics Ltd. Oxidized thiophospholipid compounds and uses thereof
KR20110095288A (ko) 2008-11-06 2011-08-24 바스큘라 바이오제닉스 리미티드 산화된 지질 화합물 및 이의 용도
SG11201400208PA (en) * 2011-09-01 2014-03-28 Vascular Biogenics Ltd Formulations and dosage forms of oxidized phospholipids
US9771385B2 (en) 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids
CN106999506A (zh) 2014-11-26 2017-08-01 脉管生物生长有限公司 氧化脂质以及纤维化的治疗或预防
US10597603B2 (en) 2014-12-16 2020-03-24 Polymer Ventures, Inc. Oil recovery aid
PY1576960A (es) * 2014-12-16 2017-12-01 Polymer Ventures Auxiliar de recuperación de aceite
JP6755530B2 (ja) * 2016-09-02 2020-09-16 国立大学法人岩手大学 皮膚炎の予防又は治療用医薬組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1572226A (en) * 1977-11-03 1980-07-30 Hoechst Uk Ltd Pharmaceutical preparations in solid unit dosage form
US4970233A (en) * 1987-08-04 1990-11-13 Mchugh John E Treatment of Acquired Immunodeficiency Syndrome (AIDS) HTLV-111/LAV infections and Acquired Immunodeficiency Syndroms (AIDS) Related Complex (ARC)
WO2002053092A2 (en) 2001-01-04 2002-07-11 Vascular Biogenics Ltd. Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis
US6333348B1 (en) * 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
US20030188756A1 (en) * 2002-08-19 2003-10-09 Cantorna Margherita T Treatment of inflammatory bowel disease with vitamin d compounds
IL156015A0 (en) 2000-11-24 2003-12-23 Vascular Biogenics Ltd Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US6838452B2 (en) * 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US20060258692A1 (en) * 2002-10-31 2006-11-16 Mark Pines Quinazolinone compositions for regulation of gene expression related to pathological processes
CA2541382A1 (en) * 2003-10-10 2005-04-21 Lifecycle Pharma A/S A solid dosage form comprising a fibrate and a statin
NZ553147A (en) 2004-07-09 2010-07-30 Vascular Biogenics Ltd Improved process for the preparation of oxidized phospholipids
US7807847B2 (en) 2004-07-09 2010-10-05 Vascular Biogenics Ltd. Process for the preparation of oxidized phospholipids
US8569529B2 (en) 2007-01-09 2013-10-29 Vascular Biogenics Ltd. High-purity phospholipids
US8999960B2 (en) 2008-10-08 2015-04-07 Vascular Biogenics Ltd. Oxidized thiophospholipid compounds and uses thereof
KR20110095288A (ko) 2008-11-06 2011-08-24 바스큘라 바이오제닉스 리미티드 산화된 지질 화합물 및 이의 용도
JP2013516455A (ja) 2010-01-05 2013-05-13 バスキュラー バイオジェニックス リミテッド Vb−201を用いた治療
SG11201400208PA (en) 2011-09-01 2014-03-28 Vascular Biogenics Ltd Formulations and dosage forms of oxidized phospholipids

Also Published As

Publication number Publication date
CN103874485B (zh) 2017-06-09
EA029274B1 (ru) 2018-03-30
WO2013033642A1 (en) 2013-03-07
EP2750668A1 (en) 2014-07-09
KR20140078641A (ko) 2014-06-25
ES2768266T3 (es) 2020-06-22
IL231222B (en) 2018-01-31
EP2750668B1 (en) 2019-12-11
AU2012301602A1 (en) 2013-05-02
MX357759B (es) 2018-07-24
MX2014002362A (es) 2014-04-30
BR112014004916B1 (pt) 2021-12-21
US20160220590A1 (en) 2016-08-04
HK1198430A1 (en) 2015-04-24
SG11201400208PA (en) 2014-03-28
AU2012301602B2 (en) 2015-09-03
IL231222A0 (en) 2014-04-30
CA2847218A1 (en) 2013-03-07
CA2847218C (en) 2018-02-27
US20130209555A1 (en) 2013-08-15
NZ621710A (en) 2015-10-30
ZA201401478B (en) 2016-09-28
KR101939430B1 (ko) 2019-01-16
JP2014525463A (ja) 2014-09-29
EA201490544A1 (ru) 2014-08-29
CN103874485A (zh) 2014-06-18
BR112014004916A2 (pt) 2017-04-04
US9254297B2 (en) 2016-02-09
US20190008880A1 (en) 2019-01-10

Similar Documents

Publication Publication Date Title
JP2014525463A (ja) 酸化リン脂質の製剤および剤形
CN103179957B (zh) 含dgat1抑制剂的药物组合物
TW201002691A (en) Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
KR20080016952A (ko) 나노입자형 클로피도그렐과 아스피린의 배합 제제
KR20160087658A (ko) 안정성이 개선된 정제형태의 두타스테리드 조성물
JP2022509463A (ja) 非クルクミノイドの水溶性粒子とクルクミノイドの水溶性粒子から構成される製剤
KR101830142B1 (ko) 벤다무스틴의 경구 투약 형태
EP1929997A1 (en) Oxcarbazepine formulations
CN112261936A (zh) 硅酸制剂及其用途
US20160287524A1 (en) Pharmaceutical compositions comprising an active agent
HK1198430B (en) Formulations and dosage forms of oxidized phospholipids
NZ621710B2 (en) Formulations and dosage forms of oxidized phospholipids
JP5774308B2 (ja) 水溶性ビノレルビン塩の安定な医薬組成物
JP7847966B2 (ja) 医薬製剤およびその製造方法
JP2009508855A (ja) 医薬品用微粒子状脂質組成物
JP4544856B2 (ja) プランルカスト水和物含有製剤
KR101012903B1 (ko) 나노입자 형성을 이용하는 리세드로네이트 경질캡슐
WO2025132620A1 (en) Stable soft capsule preparations with solid fill for moisture sensitive active ingredients
HK40042704A (en) Silicic acid formulation and use thereof
CN117915913A (zh) 包含奥特康唑的组合物
JP2009539940A (ja) 微水溶性活性物質の経口製薬学的組成物
WO2009004592A1 (en) Vancomycin compositions
EA046569B1 (ru) Композиция кремниевой кислоты и ее применение
HK1179865A (en) Oral dosage forms of bendamustine
HK1200712B (en) Stable formulations of antiplatelet agents, omega-3 fatty acids and amylose in soft gelatin capsules

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150812

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150812

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160526

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161116

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170206

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170307

R150 Certificate of patent or registration of utility model

Ref document number: 6109175

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees